Allergan PLC (AGN)

223.12
1.24 0.55
NYSE : Health Care
Prev Close 224.36
Open 224.41
Day Low/High 222.95 / 225.14
52 Wk Low/High 184.50 / 261.27
Volume 1.70M
Avg Volume 2.66M
Exchange NYSE
Shares Outstanding 335.87M
Market Cap 75.36B
EPS 38.20
P/E Ratio N/A
Div & Yield 2.80 (1.20%)

Latest News

Weekly Roundup

Markets rebound amid headlines about oil, Trump and other news. Portfolio moves include an airline downgrade.

Shark Bites: Focus on the 'Little Picture'

Shark Bites: Focus on the 'Little Picture'

Here's what I'm trading today amid the 'flat with a positive tone' action.

Kristin Chenoweth Kicks Off 'Less Red, More You' Campaign To Launch RHOFADE™ (Oxymetazoline HCL) Cream, 1%

REKNOWNED ACTRESS AND SINGER TO HOST LAUNCH EVENT TO RAISE AWARENESS OF NEW TREATMENT FOR PERSISTENT FACIAL REDNESS ASSOCIATED WITH ROSACEA(1)

Has Allergan's Pullback Run Its Course?

Has Allergan's Pullback Run Its Course?

We make our case.

There You Have It; The Day's Trades: Doug Kass' Views

There You Have It; The Day's Trades: Doug Kass' Views

Doug Kass shares his thoughts on whether there's any there, there, and reveals some recent trades.

Weekly Roundup

Markets start to recover from one really bad day amid more political turmoil. Portfolio moves include initiating a position in an ETF.

Cramer: Carl Icahn Was Right to Sell Apple at $95

Cramer: Carl Icahn Was Right to Sell Apple at $95

What's right for a hedge fund manager sitting on a big gain, isn't necessarily right for you.

Jim Cramer on Citigroup's Downgrade of Pfizer

Jim Cramer on Citigroup's Downgrade of Pfizer

TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer said earnings matter more than a Citigroup note saying that Pfizer may buy Allergan.

Here's What Carl Icahn Bought and Sold in the First Quarter

Here's What Carl Icahn Bought and Sold in the First Quarter

Carl Icahn exited his positions in Allergan and Nuance Communications during the first quarter of the year and acquired a stake in a Xerox spinoff after pressuring for a split.

Biotech Movers: Akebia, Editas, Novavax

Biotech Movers: Akebia, Editas, Novavax

Akebia Therapeutics, Editas Medicine and Novavax were among the biotech movers in premarket trading on Tuesday.

Allergan's Eyepowerment™ Campaign Releases Survey Revealing The Importance Of Eye Language And The Crucial Role It Plays In Our Communications

-- Approximately Half of Americans Surveyed Notice the Eyes First, Supporting the Mission of the Campaign to Empower Chronic Dry Eye Sufferers to Take Action --

These Stocks Show Change of Direction

These Stocks Show Change of Direction

Finding bullish and bearish reversals in the market.

The Good, the Bad and the Ugly; Short Discourse on Disney: Doug Kass' Views

The Good, the Bad and the Ugly; Short Discourse on Disney: Doug Kass' Views

Doug Kass shares his thoughts on Nvidia, Coty and Electronic Arts.

Still an Allergan Fan; Oil Vey!: Doug Kass' Views

Still an Allergan Fan; Oil Vey!: Doug Kass' Views

Doug Kass shares his thoughts on Allergan and oil.

STMicroelectronics, Chipotle, Simpson Manufacturing: 'Mad Money' Lightning Round

STMicroelectronics, Chipotle, Simpson Manufacturing: 'Mad Money' Lightning Round

Jim Cramer is bullish on STMicroelectronics, Chipotle Mexican Grill, Simpson Manufacturing.

Masimo: Cramer's Top Takeaways

Masimo: Cramer's Top Takeaways

Joe Kiani, founder, chairman and CEO of Masimo, tells Jim Cramer about his company's great earnings.

Tableau Software: Cramer's Top Takeaways

Tableau Software: Cramer's Top Takeaways

Adam Selipsky, president and CEO of Tableau Software, tells Jim Cramer about what this visual analytics platform can do for business.

Pentair: Cramer's Top Takeaways

Pentair: Cramer's Top Takeaways

Randy Hogan, chairman and CEO of Pentair, tells Jim Cramer the company will focus on water quality and sustainability.

Hain Prompts Hesitation; 5 Rules for When a Stock Breaks Down: Jim Cramer's Best Blog

Hain Prompts Hesitation; 5 Rules for When a Stock Breaks Down: Jim Cramer's Best Blog

Jim Cramer discusses Hain and also talks about some rules to follow when a stock breaks down.

Earnings Are Still Calling the Tune: Cramer's 'Mad Money' Recap (Friday 5/12/17)

Earnings Are Still Calling the Tune: Cramer's 'Mad Money' Recap (Friday 5/12/17)

Jim Cramer lays out next week's game plan: Tech stocks look strong, but same-store sales are sinking retail.

Weekly Roundup

FBI firing, French election, oil prices, retail earnings -- and, oh yes, the markets -- create a dizzying week. We add to a few portfolio positions.

Ignore That Man in the White House? Cramer's 'Mad Money' Recap (Wednesday 5/10/17)

Ignore That Man in the White House? Cramer's 'Mad Money' Recap (Wednesday 5/10/17)

Jim Cramer says he's amazed that stocks -- and gold, even -- are just yawning at Trump's move to fire FBI Director Comey.